Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care and shown remarkable efficacy clinically. This efficacy is, however, limited to subsets of patients with significant infiltration of lymphocytes into the tumour microenvironment. To extend their efficacy to patients who fail to respond or achieve durable responses, it is now becoming evident that complex combinations of immunomodulatory agents may be required to extend efficacy to patients with immunologically "cold" tumours. Oncolytic viruses (OVs) have the capacity to selectively replicate within and kill tumour cells, resulting in the induction of immunogenic cell death and the augmentation of anti-tumour immunity, and have emerged as a promising modality for combination therapy to overcome the limitations seen with ICI

SUBMITTER: Lovatt C 

PROVIDER: S-EPMC10453115 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature